$MGNX
MACROGENICS INC

2013 Form 10-K Financial Statement

#000119312514108048 Filed on March 20, 2014

View on sec.gov

Income Statement

Concept 2013 2012 Q4 2012 Q3
Revenue $58.04M $9.799M $16.08M
YoY Change -9.07%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $11.10M $3.500M $1.500M
YoY Change 8.82%
% of Gross Profit
Research & Development $46.58M $8.500M $11.97M
YoY Change 2.53%
% of Gross Profit
Depreciation & Amortization $1.200M $240.0K $235.5K
YoY Change 20.0%
% of Gross Profit
Operating Expenses $46.58M $12.10M $11.97M
YoY Change 2.53%
Operating Profit $366.0K $2.599M
YoY Change -95.54%
Interest Expense $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net -$627.0K $100.0K $1.557K
YoY Change -499.36%
Pretax Income -$300.0K -$2.100M $2.600M
YoY Change -103.57%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings -$261.0K -$2.105M $2.601M
YoY Change -103.12%
Net Earnings / Revenue -0.45% -21.48% 16.17%
Basic Earnings Per Share -$0.04 -$1.92 $0.00
Diluted Earnings Per Share -$0.04 -$1.92 $0.00
COMMON SHARES
Basic Shares Outstanding 6.848M shares 1.092M shares
Diluted Shares Outstanding 6.848M shares 21.50M shares

Balance Sheet

Concept 2013 2012 Q4 2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $116.5M
YoY Change 144.23%
Cash & Equivalents $116.5M $47.74M $30.45M
Short-Term Investments
Other Short-Term Assets $1.000M
YoY Change 900.0%
Inventory
Prepaid Expenses $137.6K
Receivables $2.000M $2.046M
Other Receivables $0.00
Total Short-Term Assets $119.5M $49.93M
YoY Change 139.48%
LONG-TERM ASSETS
Property, Plant & Equipment $5.000M $3.268M
YoY Change 51.52%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.300M $147.2K
YoY Change 116.67%
Total Long-Term Assets $6.300M $3.820M
YoY Change 65.79%
TOTAL ASSETS
Total Short-Term Assets $119.5M $49.93M
Total Long-Term Assets $6.300M $3.820M
Total Assets $125.8M $53.75M
YoY Change 134.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.200M $3.739M
YoY Change -13.51%
Accrued Expenses $3.600M $1.237M
YoY Change 200.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $1.400M
YoY Change 133.33%
Total Short-Term Liabilities $28.80M $29.73M
YoY Change -3.03%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change -100.0%
Other Long-Term Liabilities $18.00M
YoY Change -21.05%
Total Long-Term Liabilities $18.00M
YoY Change -44.1%
TOTAL LIABILITIES
Total Short-Term Liabilities $28.80M $29.73M
Total Long-Term Liabilities $18.00M
Total Liabilities $46.90M $61.98M
YoY Change -24.35%
SHAREHOLDERS EQUITY
Retained Earnings -$175.5M
YoY Change
Common Stock $10.99K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $57.74K
YoY Change
Treasury Stock Shares
Shareholders Equity $78.90M -$8.238M
YoY Change
Total Liabilities & Shareholders Equity $125.8M $53.75M
YoY Change 134.26%

Cashflow Statement

Concept 2013 2012 Q4 2012 Q3
OPERATING ACTIVITIES
Net Income -$261.0K -$2.105M $2.601M
YoY Change -103.12%
Depreciation, Depletion And Amortization $1.200M $240.0K $235.5K
YoY Change 20.0%
Cash From Operating Activities -$14.17M $17.70M -$6.320M
YoY Change 115.32%
INVESTING ACTIVITIES
Capital Expenditures $2.961M -$410.0K -$280.0K
YoY Change 215.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$2.961M -$410.0K -$280.0K
YoY Change 214.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $84.77M
YoY Change 180934.04%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 85.87M 10.00K 10.00K
YoY Change 183283.49%
NET CHANGE
Cash From Operating Activities -14.17M 17.70M -6.320M
Cash From Investing Activities -2.961M -410.0K -280.0K
Cash From Financing Activities 85.87M 10.00K 10.00K
Net Change In Cash 68.74M 17.30M -6.590M
YoY Change -1019.55%
FREE CASH FLOW
Cash From Operating Activities -$14.17M $17.70M -$6.320M
Capital Expenditures $2.961M -$410.0K -$280.0K
Free Cash Flow -$17.13M $18.11M -$6.040M
YoY Change 127.77%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2003Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
2051644 shares
CY2006Q2 us-gaap Shares Issued
SharesIssued
10003300 shares
CY2014Q1 dei Entity Public Float
EntityPublicFloat
698022185
CY2014Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27471329 shares
CY2011Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.94
CY2005Q2 mgnx Additional Payment Upon Achievement Of Milestone
AdditionalPaymentUponAchievementOfMilestone
10950000
CY2005Q2 mgnx Number Of Potential Shares To Be Issued As Additional Consideration Under Asset Purchase Agreement
NumberOfPotentialSharesToBeIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement
36135 shares
CY2008Q3 mgnx Onetime Milestone Payment To Be Paid Under Agreement
OnetimeMilestonePaymentToBePaidUnderAgreement
5000000
CY2004Q4 us-gaap Shares Issued
SharesIssued
13604016 shares
CY2010Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1246025
CY2010Q4 us-gaap Stockholders Equity
StockholdersEquity
-38634058
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36876018
CY2011Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1533986
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
-17484284
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
55218361
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1098914 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.94
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3249541 shares
CY2012Q4 us-gaap Treasury Stock Number Of Shares Held
TreasuryStockNumberOfSharesHeld
14381 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
425000000 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2012Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
628768
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1237025
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
14339497
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
164334646
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3739125
CY2012Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
78090021
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
29728094
CY2012Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1592357
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-8237308
CY2012Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
52947
CY2012Q4 us-gaap Impaired Financing Receivable Related Allowance
ImpairedFinancingReceivableRelatedAllowance
0
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-175472403
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
24123176
CY2012Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
2801653
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
10989
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
53746900
CY2012Q4 us-gaap Restructuring Reserve Noncurrent
RestructuringReserveNoncurrent
9445171
CY2012Q4 us-gaap Liabilities
Liabilities
61984208
CY2012Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
2800000
CY2012Q4 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
52947
CY2012Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
19956343
CY2012Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
1100000
CY2012Q4 us-gaap Assets Current
AssetsCurrent
49927008
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
147246
CY2012Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
137634
CY2012Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
3521722
CY2012Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
78090021
CY2012Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
404850
CY2012Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
18695197
CY2012Q4 us-gaap Assets
Assets
53746900
CY2012Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
48148005
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47743155
CY2012Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2012Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2046219
CY2012Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
1247772
CY2012Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
17607293
CY2012Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
5218002
CY2012Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2777899
CY2012Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
9379064
CY2012Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
35330167
CY2012Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Other
DeferredTaxAssetsTaxCreditCarryforwardsOther
19039613
CY2012Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1575782
CY2012Q4 us-gaap Treasury Stock Value
TreasuryStockValue
57742
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3267796
CY2012Q4 mgnx Restricted Cash Fair Value Disclosure
RestrictedCashFairValueDisclosure
404850
CY2012Q4 mgnx Money Market Funds Fair Value Disclosure
MoneyMarketFundsFairValueDisclosure
29047958
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25177597 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1688251 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.90
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3200958 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
4.64
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3022948 shares
CY2013Q4 us-gaap Treasury Stock Number Of Shares Held
TreasuryStockNumberOfSharesHeld
14381 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.94
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
1438742
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3583552
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
3310884
CY2013Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
394952
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
15532837
CY2013Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
394952
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
254453673
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
16665430
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3169034
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
3512517
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
79376945
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
28821571
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1707859
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
78914468
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
2780398
CY2013Q4 us-gaap Impaired Financing Receivable Related Allowance
ImpairedFinancingReceivableRelatedAllowance
0
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-175733238
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
20267323
CY2013Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
2904227
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
251775
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
125782381
CY2013Q4 us-gaap Restructuring Reserve Noncurrent
RestructuringReserveNoncurrent
8006428
CY2013Q4 us-gaap Liabilities
Liabilities
46867913
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
3410210
CY2013Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
2900000
CY2013Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
362920
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
7135687
CY2013Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
3651421
CY2013Q4 us-gaap Unrecognized Tax Benefits Resulting In Net Operating Loss Carryforward
UnrecognizedTaxBenefitsResultingInNetOperatingLossCarryforward
1800000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
119457133
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
885166
CY2013Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
971705
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
3315514
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
79771897
CY2013Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
404850
CY2013Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
90434435
CY2013Q4 us-gaap Assets
Assets
125782381
CY2013Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
116886259
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
64574000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
116481409
CY2013Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2013Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2004019
CY2013Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
1438477
CY2013Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
394952
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
20568069
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
5132458
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3785612
CY2013Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
42311000
CY2013Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
8216695
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
67532000
CY2013Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
7600000
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
36561195
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Other
DeferredTaxAssetsTaxCreditCarryforwardsOther
19883076
CY2013Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1438870
CY2013Q4 us-gaap Treasury Stock Value
TreasuryStockValue
57742
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5035232
CY2013Q4 mgnx Restricted Cash Fair Value Disclosure
RestrictedCashFairValueDisclosure
404850
CY2013Q4 mgnx Money Market Funds Fair Value Disclosure
MoneyMarketFundsFairValueDisclosure
26046974
CY2013Q4 mgnx Operating Loss Carryforwards Not Subject To Limitation
OperatingLossCarryforwardsNotSubjectToLimitation
96300000
mgnx Amount Of Additional Consideration Paid Under Agreement
AmountOfAdditionalConsiderationPaidUnderAgreement
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
1739116 shares
mgnx Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized After Increase
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease
3790760 shares
CY2011Q1 mgnx Stock Option Exchange Ratio Description
StockOptionExchangeRatioDescription
one-for-one basis
CY2002Q3 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
1.00 pure
CY2002Q3 mgnx Employee Eligible Age To Participate In Benefit Plan
EmployeeEligibleAgeToParticipateInBenefitPlan
21 Age
CY2008Q3 mgnx Lease Expiration Year
LeaseExpirationYear
2018
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0135 pure
CY2011 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2011 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1025602 shares
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.62 pure
CY2011 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
shares
CY2011 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2011 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Discount For Postvesting Restrictions
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions
0.0558 pure
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.94
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2011 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
6757340
CY2011 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1025602 shares
CY2011 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
49883 shares
CY2011 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
CY2011 us-gaap Revenues
Revenues
57207366
CY2011 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
287961
CY2011 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1108107
CY2011 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1467444
CY2011 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
70400
CY2011 us-gaap Income Tax Reconciliation Tax Credits Other
IncomeTaxReconciliationTaxCreditsOther
7056607
CY2011 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
133782
CY2011 us-gaap Revenue From Grants
RevenueFromGrants
10152969
CY2011 us-gaap Operating Income Loss
OperatingIncomeLoss
5249676
CY2011 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-76876
CY2011 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-12551066
CY2011 us-gaap Net Income Loss
NetIncomeLoss
6717120
CY2011 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2347439
CY2011 us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
513
CY2011 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
12014815
CY2011 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
500213
CY2011 us-gaap License And Services Revenue
LicenseAndServicesRevenue
47054397
CY2011 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1459435
CY2011 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
4696
CY2011 us-gaap Costs And Expenses
CostsAndExpenses
51957690
CY2011 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10868791
CY2011 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12085216
CY2011 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2991131
CY2011 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
CY2011 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-4275976
CY2011 us-gaap Share Based Compensation
ShareBasedCompensation
2347439
CY2011 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
18342343
CY2011 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-500213
CY2011 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
725811
CY2011 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2900000
CY2011 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
217097
CY2011 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
272988
CY2011 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
1480185
CY2011 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-10271048
CY2011 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
70400
CY2011 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
2350992
CY2011 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
41088899
CY2011 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
53225
CY2011 us-gaap Undistributed Earnings Allocated To Participating Securities
UndistributedEarningsAllocatedToParticipatingSecurities
6717120
CY2011 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1100000
CY2011 us-gaap Increase Decrease In Restructuring Reserve
IncreaseDecreaseInRestructuringReserve
-447019
CY2011 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2011 us-gaap Participating Securities Distributed And Undistributed Earnings
ParticipatingSecuritiesDistributedAndUndistributedEarnings
6717120
CY2011 us-gaap Depreciation
Depreciation
1147300
CY2011 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2347439
CY2011 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2011 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
CY2011 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
12014816
CY2011 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2011 mgnx Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
232324
CY2011 mgnx Sharebased Compensation Arrangement By Sharebased Payment Award Option Exercised Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionExercisedIntrinsicValue
102418
CY2011 mgnx Income Tax Reconciliation Fair Value Adjustment Of Preferred Stock Warrant Liability
IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability
-496208
CY2011 mgnx Contingent Consideration Recorded As Incremental In Process Research And Development Expense
ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense
0
CY2013 dei Entity Registrant Name
EntityRegistrantName
MACROGENICS INC
CY2013 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2013 dei Amendment Flag
AmendmentFlag
false
CY2013 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2013 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2013 dei Document Type
DocumentType
10-K
CY2013 dei Document Period End Date
DocumentPeriodEndDate
2013-12-31
CY2013 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2000-08-14
CY2013 dei Entity Central Index Key
EntityCentralIndexKey
0001125345
CY2013 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2013 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2013 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2013 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2013 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
CY2013 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2013 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6847697 shares
CY2013 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
shares
CY2013 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-18.7739
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.11
CY2013 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M24D
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1307101 shares
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
10.70
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.91
CY2013 us-gaap Lessee Leasing Arrangements Operating Leases Renewal Term
LesseeLeasingArrangementsOperatingLeasesRenewalTerm
P5Y
CY2013 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14172123
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.85
CY2013 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P4Y
CY2013 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6847697 shares
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y9M18D
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y9M18D
CY2013 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1268049 shares
CY2013 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Concentration of Credit Risk</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Substantially all of the Company&#x2019;s cash and cash equivalents are maintained with major financial institutions in the United States. Deposits held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, and accounts receivable. The counterparties are various corporations, financial institutions and government agencies of high credit standing.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> For the years ended December&#xA0;31, 2013, 2012 and 2011, all of the Company&#x2019;s grant revenue was related to contracts and research grants received from U.S. government agencies. Collaborations with Les Laboratoires Servier and Institut de Recherches Servier (collectively, &#x201C;Servier&#x201D;), Boehringer Ingelheim GmbH (&#x201C;Boehringer&#x201D;), Gilead Sciences, Inc. (&#x201C;Gilead&#x201D;), Pfizer, Inc. (&#x201C;Pfizer&#x201D;) and Eli Lilly&#xA0;&amp; Co. (&#x201C;Eli Lilly&#x201D;) account for all other revenue. All outstanding receivables are due from the Company&#x2019;s collaborators and U.S. government agencies.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"> The following table represents the percentage of all significant revenue earned in the periods indicated:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"> <b>Year&#xA0;Ended&#xA0;December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"> <b>&#xA0;&#xA0;&#xA0;&#xA0;2013&#xA0;&#xA0;&#xA0;&#xA0;</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"> <b>&#xA0;&#xA0;&#xA0;&#xA0;2012&#xA0;&#xA0;&#xA0;&#xA0;</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"> <b>&#xA0;&#xA0;&#xA0;&#xA0;2011&#xA0;&#xA0;&#xA0;&#xA0;</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Servier</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">51.6</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">17.3</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Boehringer</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">24.8</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">18.4</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">15.6</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Gilead</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">13.8</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Pfizer</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6.0</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">8.7</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">10.8</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Government Agencies</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.2</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6.5</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">17.7</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Eli Lilly</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.4</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">48.9</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">54.0</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The following table represents the percentage of all significant accounts receivable:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="75%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"> <b>&#xA0;&#xA0;&#xA0;&#xA0;2013&#xA0;&#xA0;&#xA0;&#xA0;</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"> <b>&#xA0;&#xA0;&#xA0;&#xA0;2012&#xA0;&#xA0;&#xA0;&#xA0;</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Gilead</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">53.4</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Pfizer.</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">12.3</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">45.4</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Boehringer</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">12.2</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">18.0</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Eli Lilly</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7.0</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">28.2</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Servier</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6.4</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Government Agencies</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4.6</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">8.4</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> </table> </div>
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
87635 shares
CY2013 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of the financial statements in accordance with generally accepted accounting principles (&#x201C;GAAP&#x201D;) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, convertible preferred stock and common stock, preferred stock warrant liability, income taxes, pre-clinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ from these estimates.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> In addition, prior to the Company&#x2019;s IPO in October 2013, the Company utilized estimates and assumptions in determining the fair value of its common stock. The Company granted stock options at exercise prices not less than the fair value of its common stock as determined by the Board of Directors, with input from management. Management used contemporaneous valuations in estimating the fair value of its common stock. The board of directors determined the estimated fair value of the common stock based on a number of objective and subjective factors, including external market considerations affecting the biotechnology industry and the historic prices at which the Company sold shares of its preferred stock.</p> </div>
CY2013 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
CY2013 us-gaap Revenues
Revenues
58034668
CY2013 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
115502
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
487603
CY2013 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-260835
CY2013 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-626814
CY2013 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1067500
CY2013 us-gaap Income Tax Reconciliation Tax Credits Other
IncomeTaxReconciliationTaxCreditsOther
843463
CY2013 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
375000
CY2013 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-260835
CY2013 us-gaap Revenue From Grants
RevenueFromGrants
1281545
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
365979
CY2013 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
834071
CY2013 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-42200
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-260835
CY2013 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
1860591
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
862162
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11086759
CY2013 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
85871153
CY2013 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1286923
CY2013 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
83622358
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2960776
CY2013 us-gaap License And Services Revenue
LicenseAndServicesRevenue
56753123
CY2013 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
626349
CY2013 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
2931
CY2013 us-gaap Costs And Expenses
CostsAndExpenses
57668689
CY2013 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
2947202
CY2013 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
-225605
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-16676509
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
862162
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
68738254
CY2013 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
241467
CY2013 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2700000
CY2013 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
252930
CY2013 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2346527
CY2013 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
609476
CY2013 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-570091
CY2013 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
85871153
CY2013 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-91293
CY2013 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2960776
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
46581930
CY2013 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1100000
CY2013 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1200000
CY2013 us-gaap Increase Decrease In Restructuring Reserve
IncreaseDecreaseInRestructuringReserve
-628769
CY2013 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2013 us-gaap Depreciation
Depreciation
1193340
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
862162
CY2013 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2013 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2013 mgnx Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
102574
CY2013 mgnx Share Based Compensation Arrangement By Share Based Payment Award Equity Instrument Number Of Shares Exchanged
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentNumberOfSharesExchanged
1921894 shares
CY2013 mgnx Income Tax Reconciliation Deferred Tax Adjustments
IncomeTaxReconciliationDeferredTaxAdjustments
-855130
CY2013 mgnx Tax Credit Carryforward Expiration Year Range End
TaxCreditCarryforwardExpirationYearRangeEnd
2033
CY2013 mgnx Income Tax Examination Year Under Examination Range Start
IncomeTaxExaminationYearUnderExaminationRangeStart
2001
CY2013 mgnx Liquid Investment Maturity Period To Be Classified As Cash Equivalent Maximum
LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum
P3M
CY2013 mgnx Operating Loss Carryforwards Limitations On Use Amount
OperatingLossCarryforwardsLimitationsOnUseAmount
8500000
CY2013 mgnx Income Tax Examination Year Under Examination Range End
IncomeTaxExaminationYearUnderExaminationRangeEnd
2012
CY2013 mgnx Tax Credit Carryforward Expiration Year Range Start
TaxCreditCarryforwardExpirationYearRangeStart
2020
CY2013 mgnx Percentage Likely Of Largest Amount Of Tax Benefit Being Realized Upon Ultimate Settlement With Taxing Authority
PercentageLikelyOfLargestAmountOfTaxBenefitBeingRealizedUponUltimateSettlementWithTaxingAuthority
0.50 pure
CY2013 mgnx Income Tax Reconciliation State Deferred Taxes Adjustments
IncomeTaxReconciliationStateDeferredTaxesAdjustments
344178
CY2013 mgnx Federal And State Net Operating Loss Carry Forwards Expiration Year Start
FederalAndStateNetOperatingLossCarryForwardsExpirationYearStart
2023
CY2013 mgnx Sharebased Compensation Arrangement By Sharebased Payment Award Option Exercised Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionExercisedIntrinsicValue
5400000
CY2013 mgnx Income Tax Reconciliation Fair Value Adjustment Of Preferred Stock Warrant Liability
IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability
218872
CY2013 mgnx Contingent Consideration Recorded As Incremental In Process Research And Development Expense
ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense
0
CY2013 mgnx Defined Contribution Plan Employees Contribution Annual Vesting Percentage
DefinedContributionPlanEmployeesContributionAnnualVestingPercentage
1.00 pure
CY2013 mgnx Federal And State Net Operating Loss Carry Forwards Expiration Year End
FederalAndStateNetOperatingLossCarryForwardsExpirationYearEnd
2033
CY2013 mgnx Operating Loss Carryforwards Limitations On Use Year Start
OperatingLossCarryforwardsLimitationsOnUseYearStart
2014
CY2013 mgnx Operating Loss Carryforwards Limitations On Use Year End
OperatingLossCarryforwardsLimitationsOnUseYearEnd
2027
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
545970 shares
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0118 pure
CY2012 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2012 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1083276 shares
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.51 pure
CY2012 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
shares
CY2012 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3M18D
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Discount For Postvesting Restrictions
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions
0.0557 pure
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.94
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2012 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6581989
CY2012 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1083276 shares
CY2012 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
863176 shares
CY2012 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
CY2012 us-gaap Revenues
Revenues
63826098
CY2012 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
58371
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
879024
CY2012 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
156445
CY2012 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
46826
CY2012 us-gaap Income Tax Reconciliation Tax Credits Other
IncomeTaxReconciliationTaxCreditsOther
4895671
CY2012 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-780
CY2012 us-gaap Revenue From Grants
RevenueFromGrants
4180279
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
8205310
CY2012 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
91160
CY2012 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1351650
CY2012 us-gaap Net Income Loss
NetIncomeLoss
8361755
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
838395
CY2012 us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
-177321
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
940043
CY2012 us-gaap License And Services Revenue
LicenseAndServicesRevenue
59645819
CY2012 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-150695
CY2012 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
7627
CY2012 us-gaap Costs And Expenses
CostsAndExpenses
55620788
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10187894
CY2012 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
46826
CY2012 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
787093
CY2012 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
CY2012 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-10810089
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
838395
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-7475206
CY2012 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
279165
CY2012 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2700000
CY2012 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
225195
CY2012 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
185200
CY2012 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
1460289
CY2012 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-7312331
CY2012 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
46826
CY2012 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
2926615
CY2012 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-940043
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
45432894
CY2012 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
46826
CY2012 us-gaap Undistributed Earnings Allocated To Participating Securities
UndistributedEarningsAllocatedToParticipatingSecurities
8361755
CY2012 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1000000
CY2012 us-gaap Increase Decrease In Restructuring Reserve
IncreaseDecreaseInRestructuringReserve
-533560
CY2012 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2012 us-gaap Participating Securities Distributed And Undistributed Earnings
ParticipatingSecuritiesDistributedAndUndistributedEarnings
8361755
CY2012 us-gaap Depreciation
Depreciation
959930
CY2012 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
838395
CY2012 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2012 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
CY2012 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2013Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.93
CY2013Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.93
CY2013Q1 us-gaap Revenues
Revenues
10598000
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-3366000
CY2012Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2012Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2012 mgnx Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
440815
CY2012 mgnx Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized After Increase
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease
4336730 shares
CY2012 mgnx Income Tax Reconciliation Deferred Tax Adjustments
IncomeTaxReconciliationDeferredTaxAdjustments
-512375
CY2012 mgnx Liquid Investment Maturity Period To Be Classified As Cash Equivalent Maximum
LiquidInvestmentMaturityPeriodToBeClassifiedAsCashEquivalentMaximum
P3M
CY2012 mgnx Sharebased Compensation Arrangement By Sharebased Payment Award Option Exercised Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionExercisedIntrinsicValue
271929
CY2012 mgnx Income Tax Reconciliation Fair Value Adjustment Of Preferred Stock Warrant Liability
IncomeTaxReconciliationFairValueAdjustmentOfPreferredStockWarrantLiability
-52743
CY2012 mgnx Contingent Consideration Recorded As Incremental In Process Research And Development Expense
ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense
0
CY2012Q1 us-gaap Revenues
Revenues
20510000
CY2012Q1 us-gaap Net Income Loss
NetIncomeLoss
4320000
CY2012Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2012Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2012Q2 us-gaap Revenues
Revenues
17435000
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
3546000
CY2013Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2013Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2013Q2 us-gaap Revenues
Revenues
12299000
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-294000
CY2012Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2012Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2012Q3 us-gaap Revenues
Revenues
16082000
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
2601000
CY2013Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.01
CY2013Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.14
CY2013Q3 us-gaap Revenues
Revenues
20232000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
6604000
CY2012Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.92
CY2012Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.92
CY2012Q4 us-gaap Revenues
Revenues
9799000
CY2012Q4 us-gaap Net Income Loss
NetIncomeLoss
-2105000
CY2013Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
CY2013Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
CY2013Q4 us-gaap Revenues
Revenues
14906000
CY2013Q4 us-gaap Net Income Loss
NetIncomeLoss
-3205000

Files In Submission

Name View Source Status
0001193125-14-108048-index-headers.html Edgar Link pending
0001193125-14-108048-index.html Edgar Link pending
0001193125-14-108048.txt Edgar Link pending
0001193125-14-108048-xbrl.zip Edgar Link pending
d644794d10k.htm Edgar Link pending
d644794dex231.htm Edgar Link pending
d644794dex311.htm Edgar Link pending
d644794dex312.htm Edgar Link pending
d644794dex321.htm Edgar Link pending
d644794dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g644794g04y47_g.jpg Edgar Link pending
g644794g18q24_g.jpg Edgar Link pending
g644794g19e20.jpg Edgar Link pending
g644794g30v39.jpg Edgar Link pending
g644794g35e13.jpg Edgar Link pending
g644794g37d02_g.jpg Edgar Link pending
g644794g37v45.jpg Edgar Link pending
g644794g49z75.jpg Edgar Link pending
g644794g54r32.jpg Edgar Link pending
g644794g63f08.jpg Edgar Link pending
g644794g73g29_g.jpg Edgar Link pending
g644794g74d12.jpg Edgar Link pending
g644794g77g14_g.jpg Edgar Link pending
g644794g79f34_g.jpg Edgar Link pending
g644794g85w60_g.jpg Edgar Link pending
g644794g97i90.jpg Edgar Link pending
mgnx-20131231.xml Edgar Link completed
mgnx-20131231.xsd Edgar Link pending
mgnx-20131231_cal.xml Edgar Link unprocessable
mgnx-20131231_def.xml Edgar Link unprocessable
mgnx-20131231_lab.xml Edgar Link unprocessable
mgnx-20131231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending